To investigate the differential metabolic impacts and clinical benefits of minimally invasive ablation versus surgical approaches in early lung adenocarcinoma.
Approach:
Study Design: The study involved 40 patients (15 ablation, 25 surgery) and utilized MALDI-MS for metabolomic profiling to characterize treatment-specific metabolic signatures.
Metabolomic Profiling: Distinct metabolic networks were identified, with supervised OPLS-DA models achieving effective group separation and identifying differentially expressed metabolites.
Diagnostic Performance: Metabolomics showed superior diagnostic efficacy (AUC = 0.79) compared to traditional imaging (0.75) and biochemical tests (0.65).
Clinical Assessment: Clinical outcomes indicated significant advantages for ablation, including shorter hospital stays, reduced costs, and fewer complications, while maintaining equivalent pulmonary function.
Key Findings:
Metabolomic profiling revealed distinct metabolic networks between ablation and surgery.
AUC for metabolomics (0.79) was superior to traditional imaging (0.75) and biochemical tests (0.65).
Integration of metabolomics, imaging, and biochemical tests improved diagnostic power (AUC = 0.85).
Ablation resulted in shorter hospital stays (P = 0.003), reduced costs, and fewer complications.
Interpretation:
The findings provide insights into treatment-induced metabolic reprogramming.
Limitations:
The study had a limited sample size (40 patients).
Further research is needed to validate findings across larger and more diverse populations.
Conclusion:
The study provides integrated metabolomic and clinical evidence supporting the use of ablation in early lung adenocarcinoma treatment.
